FGFR3 mutations in prostate cancer: association with low-grade tumors.

作者: Silvia Hernández , Silvia de Muga , Laia Agell , Nuria Juanpere , Raquel Esgueva

DOI: 10.1038/MODPATHOL.2009.46

关键词:

摘要: Prostate cancer is the second cause of cancer-related death in men Western World. The role FGFR3 and its abnormalities prostate are not known. mutations have been reported some human tumors. Few studies analyzed tumors, no previously reported. Prevalence somatic was investigated a series presence other tumors these patients, including urothelial, skin, colon, lung neoplasms, recorded. Mutational analysis exons 7, 10, 15 revealed 9 112 studied (8%). Most them consisted missense change S249C. prevalence with combined Gleason score=6 18% (8/45) compared to 3% (1/36) for grade=7, 0% (0/31) those grade >or=8 metastases (P=0.007). frequency autopsy biopsy samples 6 9%, respectively. from patients only 2% 23% associated neoplasms (P=0.001). This first report molecular changes cancer. gene does seem be central pathogenesis cancer, but it significantly subgroup low-grade finding mainly arising bladder skin.

参考文章(47)
Wallace L. McKeehan, Norman M. Greenberg, Barbara Foster, Michael M. Ittmann, Fen Wang, Kerstin McKeehan, Wei Guo, Scot Jauma, Chengliu Jin, Cooperation between Ectopic FGFR1 and Depression of FGFR2 in Induction of Prostatic Intraepithelial Neoplasia in the Mouse Prostate Cancer Research. ,vol. 63, pp. 8784- 8790 ,(2003)
Tomoko Kamiakito, Masashi Fukayama, Nobuo Hanai, Motoo Yamasaki, Morio Koike, Akira Tanaka, Yutaka Kobayashi, Hiroki Yoshida, Akiko Furuya, Ken Kuriki, High Frequency of Fibroblast Growth Factor (FGF) 8 Expression in Clinical Prostate Cancers and Breast Tissues, Immunohistochemically Demonstrated by a Newly Established Neutralizing Monoclonal Antibody against FGF 8 Cancer Research. ,vol. 58, pp. 2053- 2056 ,(1998)
William A. Horton, Gregory P. Lunstrum, Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Reviews in Endocrine & Metabolic Disorders. ,vol. 3, pp. 381- 385 ,(2002) , 10.1023/A:1020914026829
David Cappellen, Catherine De Oliveira, David Ricol, Sixtina de Medina, Jérôme Bourdin, Xavier Sastre-Garau, Dominique Chopin, Jean Paul Thiery, François Radvanyi, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics. ,vol. 23, pp. 18- 20 ,(1999) , 10.1038/12615
K Sahadevan, S Darby, HY Leung, ME Mathers, CN Robson, VJ Gnanapragasam, Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. The Journal of Pathology. ,vol. 213, pp. 82- 90 ,(2007) , 10.1002/PATH.2205
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, M. J. Thun, Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. ,vol. 57, pp. 43- 66 ,(2007) , 10.3322/CANJCLIN.57.1.43
David M. Ornitz, FGF signaling in the developing endochondral skeleton Cytokine & Growth Factor Reviews. ,vol. 16, pp. 205- 213 ,(2005) , 10.1016/J.CYTOGFR.2005.02.003
S F Winter, V D Acevedo, R D Gangula, K W Freeman, D M Spencer, N M Greenberg, Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene. ,vol. 26, pp. 4897- 4907 ,(2007) , 10.1038/SJ.ONC.1210288
Christian Hafner, Thomas Vogt, Arndt Hartmann, FGFR3 Mutations in Benign Skin Tumors Cell Cycle. ,vol. 5, pp. 2723- 2728 ,(2006) , 10.4161/CC.5.23.3509